

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	4	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	5	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	7	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	9	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	12	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	13	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	14	JAN 29	PHAR reloaded with new search and display fields
NEWS	15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	19	FEB 26	MEDLINE reloaded with enhancements
NEWS	20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	25	MAR 16	CASREACT coverage extended
NEWS	26	MAR 20	MARPAT now updated daily

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:27:21 ON 21 MAR 2007

=> file pctfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'PCTFULL' ENTERED AT 08:27:29 ON 21 MAR 2007

COPYRIGHT (C) 2007 Univentio

FILE LAST UPDATED: 20 MAR 2007 <20070320/UP>

MOST RECENT UPDATE WEEK: 200711 <200711/EW>

FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s WO 0071135/pn

L1 0 WO 0071135/PN
(WO71135/PN)

=> s WO 200071135/pn

L2 1 WO 200071135/PN
(WO2000071135/PN)

=> s l2 and leukemia

28368 LEUKEMIA

8889 LEUKEMIAS

30306 LEUKEMIA

(LEUKEMIA OR LEUKEMIAS)

L3 1 L2 AND LEUKEMIA

=> s l3 and lympho?

56381 LYMPHO?

L4 1 L3 AND LYMPHO?

=> d ibib kwic

L4 ANSWER 1 OF 1

PCTFULL COPYRIGHT 2007 Univentio on STN

ACCESSION NUMBER:

2000071135 PCTFULL ED 20020515

TITLE (ENGLISH):

ANTI-TUMOR COMPRISING BOROPROLINE COMPOUNDS

TITLE (FRENCH):

AGENTS ANTI-TUMORALES CONTENANT DES COMPOSES DE

BOROPROLINE

INVENTOR(S):

WALLNER, Barbara, P.;

MILLER, Glenn

PATENT ASSIGNEE(S):

POINT THERAPEUTICS, INC.

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER

KIND

DATE

WO 2000071135

A1 20001130

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ
TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
GA GN GW ML MR NE SN TD TG

PRIORITY INFO.:

US 1999-60/135,861

19990525

APPLICATION INFO.: WO 2000-US14505 A 20000525
PI WO 2000071135 A1 20001130

DETD . . . who have normal
hemopoietic activity. In another embodiment, the subject is HIV
negative. In certain
embodiments, the subjects are not myeloid or lymphoid
suppressed or are not candidates for
treatment with an agent which causes such suppression at the time of
treatment with the
methods. . . .

.
carcinoma, hypernephroid
carcinoma, infantile embryonal carcinoma, carcinoma in situ,
intraepidermal carcinoma,
intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell
carcinoma, lenticular
carcinoma, carcinoma lenticulare, lipomatous carcinoma,
lymphoepithelial carcinoma,
carcinoma mastitoides, carcinoma medullare, medullary carcinoma,
carcinoma melanodes,
melanotic carcinoma, mucinous carcinoma, carcinoma muciparum, carcinoma
mucocellulare,
mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, . . .

As used herein, the terms hemopoietic and hematopoietic are used
interchangeably to
mean all blood cells including myeloid and lymphoid cells.
Myeloid cells include
erythrocytes (i.e., red blood cells), macrophages, monocytes,
granulocytes including
neutrophils, eosinophils and basophils, mast cells, megakaryocytes,
platelets and dendritic
cells, and lymphoid cells include T and B lymphocytes
, thymic dendritic cells and natural
killer (NK) cells. Hemopoietic stimulation, as used herein, refers to
the increase in
hemopoietic cell numbers or. . . .

.
0); for eosinophils 0-700 per [d] (mean - 150); for
macrophages and monocytes 200-950 per [t] (mean -430); for
lymphocytes 1500-4000 per [L] (mean -2500); for erythrocytes $4.2 \times 10^6 - 6.1 \times 10^6$ per [t]; and for
platelets 13×10^9 per [t]. . . .

.
at between 500 and 1000 per [L] and
severe neutropenia at below 500 per [d]. Likewise, in adults, a
lymphocyte count at less than
1500 is considered a medically undesirable condition. In children, the
value is less than
3000. Other preselected values. . . .

.
used interchangeably. An example of an
immunocompromised subject is one infected with HIV and experiencing
AIDS-related
symptoms such as low CD4+ T lymphocyte levels. In still other
embodiments, the methods
may be used in subjects who are HIV-positive and who may be
immunocompromised,
provided that. . . .

Thus in certain embodiments, the subjects are not myeloid or
lymphoid suppressed or
are not candidates for treatment with an agent which causes such
suppression at the time of

treatment with the methods. . . in myeloid cells such as erythrocytes, neutrophils or platelets, to below protective or normal levels. Exemplary myelosuppressed conditions are hennopoietic malignancies, including leukemia and lymphoma and diseases such as chronic idiopathic neutropenia, cyclic neutropenia, anemia and thrombocytopenia. Similarly, lymphoid suppressing conditions are those which induce a reduction in lymphoid cells such as T lymphocytes. Suppression of lymphoid cells or some myeloid cells such as granulocytes is also referred to as immunosuppression since reduction in these cell types makes an individual susceptible to, inter alia, infection. Subjects may be exposed to myeloid, lymphoid or general immune suppressing conditions by the use of either immunosuppressant drugs such as cyclosporin or high dose chemotherapeutic compounds which.

iobenguane; lododoxorubicin; lporneanol, 4-; irinotecan; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide + estrogen + progesterone; leuprorelin; levarnisole; liarozole; linear polyarnine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; . . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

8.42

8.63

STN INTERNATIONAL LOGOFF AT 08:29:46 ON 21 MAR 2007